Timber Pharma: Up as partner signs supply agreement for rare skin disease drug

Trex Wind-Down

17/03/2021 14:33

** Shares of drug developer  TMBR.A  rise ~17% to $2.5;
among top pct gainers across U.S. exchanges
    ** Co's development partner AFT Pharma  AFT.NZ  signs
exclusive license and supply agreement with Desitin Arzneimittel
GmbH for the drug Pascoma, or TMB-002    
    ** Drug used to treat facial angiofibromas associated with
Tuberous Sclerosis Complex treatment  urn:newsml:reuters.com:*:nGNX2kWFWp
    ** The agreement is for supply in Europe
    ** TMBR had entered a co-development agreement with AFT in
2019 for N.America and Wednesday's agreement is included in the
scope of the previous partnership
    ** Stock down 24.3% in last 12 months

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3635;))